DIRS.INFO The most relevant business & tech news

☆ Here are Wednesday's biggest analyst calls: Nvidia, Netflix, Dell, GM, SunPower, Alphabet, Nio, Tesla, Exxon & more
▼ + stars: | 2024-05-15 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are the biggest calls on Wall Street on Wednesday: UBS reiterates Nvidia as buy UBS said it's standing by its buy rating heading into Nvidia earnings next week. Wells Fargo names Natera a top pick Wells said the fertilizer company is a new top pick at the firm. Morgan Stanley resumes Exxon as overweight Morgan Stanley resumed coverage of the stock and says it has "attractive growth at a compelling valuation." Morgan Stanley reiterates Palo Alto as overweight Morgan Stanley said it's bullish on shares of Palo Alto heading into earnings next week. Morgan Stanley names Dell a top pick Morga Stanley raised its price target on the stock and says it remains a best idea.

Persons: it's, Cantor Fitzgerald, Tesla, Canto, Tesla's, Wells, CTVA, KeyBanc, TD Cowen, Janus Henderson, Morgan Stanley, Palo, Bernstein, Mills, Campbell, underperform Bernstein, Wolfe, SunPower, Dell, Morga Stanley, Stephens, Truist, Oppenheimer, Will, DA Davidson Organizations: UBS, Nvidia, " Bank of America, Bank of America, Alphabet's, Google, JPMorgan, China, Deutsche Bank downgrades, Deutsche, Fair, Six, Sciences, NTR, Netflix, Energy, Palo Alto, Palo, Food, Tech, Barclays, General Motors, Holdings, ALC, Apple, Apple's Worldwide Developer's Conference, Will Apple, Walmart, D.A Locations: OW, Palo Alto, U.S

☆ Here are Tuesday's biggest analyst calls: Apple, Nvidia, Amazon, Tesla, Seagate, Boston Beer, Planet Fitness & more
▼ + stars: | 2024-05-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Wells Fargo reiterates Nvidia as overweight Wells increased its price target on Nvidia to $1,150 per share from $970. Jefferies upgrades Boston Beer to buy from hold Jefferies said in its upgrade of the beverage company that it sees "multiple expansion." Bank of America reiterates Apple as buy Bank of America said it's sticking with its buy rating on shares of Apple. JPMorgan upgrades Planet Fitness to overweight from neutral JPMorgan said in its has increased confidence in Planet Fitness' growth. JPMorgan upgrades Vtex to overweight from neutral JPMorgan said it sees an attractive entry point for the software-as-a-service company.

Persons: Tesla, Goldman Sachs, Goldman, it's, Wells, ests, Jefferies, Beer, Roth, Morgan Stanley, GXO's, Baird, Oppenheimer, Edwards Organizations: Barclays, Oncology, Fulcrum Therapeutics, ISI, Nvidia, Jefferies, Boston Beer, GXO Logistics, Bank of America, Apple, HSBC, Citi, Weatherford, Energy, JPMorgan, LT, Fortrea Holdings, Edison International, RBC, North, Deutsche Bank, Amazon, Deutsche, Western Digital, Seagate Locations: China, North America

☆ We added to 5 portfolio stocks in last week's oversold market. Here's the breakdown
▼ + stars: | 2024-04-21 | by ( Morgan Chittum | ) www.cnbc.com time to read: +5 min

It was a tough, choppy week for stocks, but the oversold market gave us many opportunities to put some of our cash to work selectively. Club Director of Portfolio Analysis Jeff Marks said Friday, "We're still waiting for that truly ugly open before stepping up our buys." The PC market is embarking on an upgrade and replacement cycle, which should usher more demand for Best Buy's offerings. BBY YTD mountain Best Buy YTD Tuesday Tuesday was our busiest for trades, with adds to three companies: Oil and natural gas producer Coterra Energy , Mexican beer king Constellation Brands and Best Buy. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jeff Marks, We're, Jim Cramer's, Wednesday Abbott, Abbott, Estee Lauder, Fabrizio Freda, Lauder, ABT, Jim Cramer, Jim, Brendan Mcdermid Organizations: Federal Reserve, Jim Cramer's Charitable Trust, CNBC, Club, Coterra Energy, Constellation Brands, Coterra, Hamas, Constellation, Wednesday, Abbott Laboratories, Traders, New York Stock Exchange Locations: Here's, Iran, Israel, Ukraine

☆ Abbott Labs' surprise guidance bump is a major positive for its shareholders
▼ + stars: | 2024-04-17 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

Abbott Laboratories Why we own it : Abbott is a high-quality medtech company growing at a fast clip. As Abbott's organic sales growth continues to shine, the market will realize both concerns are overblown. We also love that EPS results on Tuesday came in above the range management had forecasted — a classic case of under-promising and over-delivering. ABT YTD mountain Abbott Laboratories YTD Organic growth was very strong, up nearly 11%, marking the fifth consecutive quarter of double-digit increases. In diagnostics, where we see the impact of the decline in Covid testing sales, organic sales increased 5.4% year over year.

Persons: —, Abbott, Edwards, Robert Ford, necrotizing, Ford, they've, Jim Cramer's, ABT, Jim Cramer, Jim Organizations: Abbott Laboratories, Revenue, Abbott, Libre, Charitable Trust, ABT, Management, NEC, Protality, TBIs, CNBC, Abbott Labs Locations: U.S

☆ Health VC firm SpringTide Ventures just closed its second $65 million fund. Here's what a startup needs to get its backing.
▼ + stars: | 2024-04-17 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +5 min

Read previewAustin Walters started SpringTide Ventures in 2018 to disrupt healthcare by democratizing access to health innovations. The firm just closed its second $65 million fund to make more of those bets. A tough fundraising environmentAfter closing on its first $20 million fund, which the firm began investing out of in 2019, SpringTide originally set a $100 million target in 2021 for its second fund, Walters said. SpringTide picks a different focus area each time — most recently, home health, where the firm has invested in companies like family primary care startup Nest Health. By solving significant problems with advanced technologies, these companies have natural competitive advantages that allow them to drive outsize returns for the firm, Walters said.

Persons: —, Austin Walters, Walters, Henry Ford, We're, SpringTide, Justin Hackworth Photgraphy SpringTide, OpenLoop, outsize, SpringTidew hasn't, " Walters Organizations: Service, SpringTide Ventures, Tiger Global, Sonic Healthcare, Business, Health, Ally Bank, Troomi Wireless Locations: Boston, San Francisco, Salt Lake City, New York

☆ Johnson & Johnson tops quarterly profit estimates as medical device sales jump
▼ + stars: | 2024-04-16 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Johnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street's expectations as sales in its medical devices business surged. The company reported $21.38 billion in total sales for the first three months of 2024, up more than 2% from the same quarter in 2023. The company now expects sales of $88 billion to $88.4 billion. Separately on Tuesday, J&J said it will increase its quarterly dividend to $1.24 per share, up 4.2% from $1.19 per share.

Persons: Johnson, J Organizations: Johnson, J's, Humana, UnitedHealth, Elevance, LSEG, & $ Locations: Irvine , California

☆ Metyos has developed a wearable to monitor chronic kidney disease. Check out the 8-slide pitch deck it used to raise $2.5 million.
▼ + stars: | 2024-03-26 | by ( Riddhi Kanetkar | ) www.businessinsider.com time to read: +1 min

Paris-based Metyos has secured $2.5 million in pre-seed funding from Cenitz. The startup is developing a wearable device for patients to manage their chronic kidney disease. Check out the 8-slide pitch deck it used to raise the funding. AdvertisementMedtech startup Metyos has secured $2.5 million in pre-seed funding from French investor Cenitz. The Paris-based startup, which launched in 2021, is creating a remote biosensor that patients can use to track their chronic kidney disease (CKD).

Persons: Metyos, —, Cenitz Organizations: Service, Business Locations: Paris, Cenitz

☆ Nvidia's AI ambitions in medicine and health care are becoming clear
▼ + stars: | 2024-03-24 | by ( Michelle Castillo | ) www.cnbc.com time to read: +3 min

Last week, Nvidia announced deals with Johnson & Johnson for use of generative AI in surgery, and with GE Healthcare to improve medical imaging. "Health care, whether it's biotechnology, chemicals, or drug discovery is a very powerful area." About 41 percent of biotech CEOs surveyed by EY in late 2023 said they were looking at "concrete" ways generative AI could be used for their companies. "This is very high for my experience, having been 30 years in this industry," Ural said. It also partnered in 2021 with Schrödinger for drug discovery.

Persons: Johnson, Raj Joshi, It's, EY, it's, Colette Kress, Roche's Genentech Organizations: Nvidia, Johnson, GE Healthcare, Companies, NVIDIA, NVIDIA BioNeMo Locations: Arda, Americas, Ural, NVIDIA Clara

☆ Nvidia and Johnson & Johnson to develop new AI applications for surgery
▼ + stars: | 2024-03-18 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +2 min

Johnson & Johnson on Monday announced it is working with Nvidia to develop and scale new artificial intelligence applications for surgery. For instance, the companies are using AI to analyze surgical video and automate the time-consuming documentation required after a procedure. Powell said Nvidia has worked in medical devices and imaging for more than a decade. More accessible surgical video means residents will not have to solely depend on the insight and availability of the more experienced physicians at their institutions. They look at game tape, and they get better over time as they look at themselves," Jegatheeswaran told CNBC in an interview.

Persons: Johnson, Kimberly Powell, Powell, Shan Jegatheeswaran, J MedTech, Jegatheeswaran Organizations: Nvidia, CNBC

☆ Stocks making the biggest moves midday: Tesla, GE HealthCare, Coinbase and more
▼ + stars: | 2024-03-13 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Crypto stocks — Stocks whose performance is tied to the price of bitcoin rose as the cryptocurrency pushed to another record for the third day in a row. Dollar Tree posted adjusted earnings of $2.55 per share on $8.64 billion of revenue for the fourth quarter. Analysts surveyed by LSEG, formerly known as Refinitiv, had penciled in $2.65 per share on $8.67 billion in revenue. GE HealthCare — Shares dropped 3% after the medtech company announced a secondary offering of 13 million shares. Analysts had expected earnings of 2 cents per share on revenue of $1.62 billion, per LSEG.

Persons: Coinbase, MicroStrategy, CleanSpark, Baird, Goldman Sachs, Wells, Raymond James, —, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Pia Singh, Michelle Fox Organizations: Marathon, Iris Energy, Texas, Nvidia, Devices, Micron Technology —, Micron, AMD, LSEG, GE, —, GE HealthCare Technologies, General Electric, Royal, Petco, Wellness Locations: Kentucky, Royal Caribbean

☆ Wall Street shrugs off the inflation report — plus, updates from a key health-care stock
▼ + stars: | 2024-03-12 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

GE Healthcare updates: GE Healthcare CFO Jay Saccaro spoke at Oppenheimer's annual Healthcare MedTech & Services conference. Saccaro expects GE Healthcare to commence stock buybacks at some point, but that's still down the road. GE Healthcare shares fell about 1% Tuesday, but the move doesn't seem tied to the presentation. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jay Saccaro, Saccaro, that's, Jim Cramer's, Jim, Yi Haifei Organizations: CNBC, Oracle, Nvidia, Nasdaq, GE Healthcare, GE, Services, U.S, Jim Cramer's Charitable Trust, Jim Cramer's Charitable, Fair for Trade, China National Convention Center, China News Service, Getty Locations: China, Williams, Sonoma, Beijing

☆ Here are Tuesday's biggest analyst calls: Apple, Tesla, Coinbase, Sony, Oracle, FedEx, Nike, Carvana & more
▼ + stars: | 2024-03-12 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

"We initiate coverage on Regeneron with an Outperform rating and $1,125 price target." Canaccord reiterates MicroStrategy as buy Canaccord raised its price target on the crypto company to $1,810 per share from $975. "We are initiating coverage of The New York Times with a Buy rating and a $52 target price. "DG – Upgrading to Neutral Raising Price Target to $158." "We are initiating coverage of Central Garden & Pet ( CENT) with a BUY rating and $52 price target."

Persons: Bernstein, Morgan Stanley, Tesla, it's, optionality, Canaccord, Goldman Sachs, PDD, Goldman, Jefferies, underperform Jefferies, Raymond James, underperform Raymond James, Argus, Evercore, William Blair, Goldman Sacks Organizations: Citi, New York Times, Nike, JPMorgan, RBC, Bank of America, Apple, Oracle, Central, FedEx, Macquarie, Sony Locations: China

☆ We're bracing for more choppiness in the market ahead as AI trade wobbles
▼ + stars: | 2024-03-11 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Many observers are arguing that some pockets of the market, mainly in the AI trade, have moved too far, too fast and are ripe for pullbacks. Meanwhile, we'll be keeping an eye on Club holding GE Healthcare's appearance Tuesday at Oppenheimer's MedTech and Services conference. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, industrials, there's, we'll, Oppenheimer's, Jim Cramer's, Jim Organizations: CNBC, Nvidia, Club, Linde, Nasdaq, FMC Corp, Procter, Gamble, Truist, Energy, EQT Corp, Boeing, of Justice, Alaska Airlines, Howmet Aerospace, Tech, Oracle, GE, Services, Jim Cramer's Charitable Locations: Albemarle, Newmont

☆ Tesla is one of the most oversold stocks in the S&P 500 and could be due for a bounce
▼ + stars: | 2024-02-02 | by ( Pia Singh | ) www.cnbc.com time to read: +5 min

Using the CNBC Pro Stock Screener tool, we screened for the most overbought and oversold names in the S & P 500 based on their 14-day relative strength index, or RSI. Stocks with a 14-day RSI greater than 70 are considered overbought, meaning they could be at risk of a pullback. Conversely, stocks with a reading lower than 30 typically means that they're oversold and possibly gearing up for a short-term bounce. Energy tech services provider Baker Hughes was one of the few oversold names that analysts have a buy rating on, according to CNBC's screen. Of the overbought names, Boston Scientific has the highest potential upside according to analysts surveyed by LSEG, at about 9.3%.

Persons: Jerome Powell, BYD, Robinson, Baker Hughes Organizations: Federal, Dow Jones, Nasdaq, CNBC, Stock, EV, Tesla, Transportation, Energy, United Parcel Service, Company, Pharma, Merck, Facebook, Boston Scientific, LSEG, Mastercard Locations: Minnesota, Thursday's

☆ Here are Thursday's biggest analyst calls: Nvidia, Apple, Microsoft, Qualcomm, Target, AT&T, Tesla & more
▼ + stars: | 2024-02-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Thursday's biggest calls on Wall Street: Morgan Stanley downgrades ZoomInfo to equal weight from overweight Morgan Stanley said it sees a slowing recovery for the software company. Morgan Stanley reiterates General Motors as overweight Morgan Stanley said it's standing by the auto giant and that GM shares are "cheap." Mizuho reiterates Nvidia as buy Mizuho said it's standing by the stock heading into its GTC Conference in March. Morgan Stanley names Docebo a top pick Morgan Stanley named the ed-tech company a top pick. " Morgan Stanley reiterates Bloom Energy as overweight Morgan Stanley said the energy company is an "underappreciated AI winner."

Persons: Morgan Stanley downgrades ZoomInfo, Morgan Stanley, Oppenheimer, AAPL, it's, Mizuho, Goldman Sachs, Goldman, Redburn, Tesla, Daiwa, Jefferies, StoneCo, Wells, JPMorgan downgrades Lennox, LII, Docebo, Kraft Heinz, Mondelez, Kate McShane, Wolfe, Cash Organizations: OW, Apple, Motors, Nvidia, Conference, Citi, Qualcomm, Samsung, Deutsche Bank, Deutsche, Humana, Microsoft, Rockwell Automation, Rockwell, JPMorgan, UBS, SilverBow Resources, Regency, Kraft, Target, RBC downgrades New York Community Bancorp, RBC, New, Community Bancorp, Bloom Energy, Boston Scientific, Mizuho Locations: Boston

☆ Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump
▼ + stars: | 2024-01-23 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

The stock trading graph of Johnson & Johnson is seen on a smartphone screen. Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's expectations as sales in the company's pharmaceutical and medical devices businesses surged. J&J also provided full-year guidance for 2024, forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share. The pharmaceutical giant reported net income of $4.13 billion, or $1.70 per share during the quarter. J&J is now zeroing in on its pharmaceutical and medical devices divisions to drive growth.

Persons: Johnson, J Organizations: LSEG

☆ 'A trove of rebound opportunities': Strategists turn bullish on biotech and more, picking top stocks
▼ + stars: | 2024-01-17 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

2023 wasn't a good year for the health-care sector, but some investors expect it to make a comeback this year — highlighting biotech and medical tech as areas to watch. But now, Citi believes that "astute investors may find themselves with a trove of rebound opportunities." Citi's top picks in biotech include Biomea Fusion , Alnylam Pharmaceuticals , and Immunovant . Jared Holz, health-care sector strategist at Mizuho Securities Americas, named biotech firm Biogen as one of his top trading ideas for 2024. "Biotech has commanded everyone's attention, but the recovery of many best-in-class medical device companies post the GLP-1 selloff has been remarkable," Orton said.

Persons: There's, Jared Holz, Biogen, Trent, medtech, Matt Orton, Orton Organizations: Citi Global Wealth Investments, U.S . Healthcare, Citi, Biomea, Alnylam Pharmaceuticals, Mizuho Securities Americas, Biogen, medtech, Raymond James Investment Management, Medical, Biotech, Abbott Laboratories Locations: U.S, Alphinity, medtech

☆ Apple has to stop selling its newest watches with a blood oxygen feature in the US — again
▼ + stars: | 2024-01-17 | by ( Kylie Kirschner | ) www.businessinsider.com time to read: +2 min

Apple must stop selling its Series 9 and Ultra 2 watches with blood oxygen monitoring functionality. A US court denied Apple's request for a longer pause on an import ban of the watches. It will now, again, have to stop selling the two watch models that feature the contentious blood oxygen function until the appeal is resolved. Apple has appealed the ITC's ruling, arguing that the import ban will cause "irreparable harm" to its business. AdvertisementThe company won't be able to sell its smartwatches with the blood oxygen feature at least until its appeal of the import ban is resolved, a period that Apple expects will last at least a year.

Persons: —, Biden Organizations: Apple, Service, International Trade Commission, Appeals, Federal Circuit, ITC, Customs, Border Protection

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ VCs are getting pickier about their weight-loss bets as startups rush to prescribe Ozempic
▼ + stars: | 2023-12-11 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +8 min

Read previewWith the Ozempic craze in full swing, investors are getting picky about the weight-loss startups they want to back. Kaganoff predicted that in the new year some startups prescribing GLP-1s would invest more money in studies using real-world evidence to show their programs work. And despite the Ozempic frenzy, weight-loss startups captured a tiny fraction of the money invested this year. Investors had put about $211 million toward weight-loss startups through mid-November, representing about 3% of digital-health funding over that period, according to PitchBook. Alfie HealthSome unlikely sectors of the healthcare industry stand to benefit from the growth of the weight-loss market.

Persons: —, Sari Kaganoff, Crystal Cox, Kaganoff, Ro, VCs, Michael Greeley, Alyssa Jaffee, 7wireVentures, she's, she'd, Mounjaro, Mercer, Michael Siluk, PitchBook, Alfie Health, it's, Alfie's cofounders, Aaron DeGagne, Jordan, he'd, DeGagne, There's Organizations: Service, Business, Rock Health, Flare Capital Partners, Getty, Employers, Health, Investors, Phenomix Sciences, Mayo Clinic, PitchBook, Tusk Venture Partners, Sword Health Locations: GLP

☆ Here are Friday's biggest analyst calls: Tesla, Boeing, Amazon, Delta, Spotify, Alibaba, Johnson & Johnson and more
▼ + stars: | 2023-12-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Here are the biggest calls on Wall Street on Friday: Stifel initiates Boeing at buy Stifel said it sees a "favorable" setup for Boeing shares. Citi downgrades Spotify to neutral from buy Citi said in its downgrade of Spotify that the risk/reward is less compelling. Jefferies initiates Arcos Dorados as a buy Jefferies said the Latin American McDonald's franchisee is a "consistent compounder." Jefferies initiates CSG Systems as buy Jefferies said in its initiation of the software-as-a-service company that it sees burgeoning growth. Jefferies initiates Amdocs as buy Jefferies said it sees opportunity for the Israel-based software and systems integration supplier. "

Persons: Stifel, TD Cowen, Morgan Stanley downgrades Alibaba, Morgan Stanley, it's, Alibaba, Tesla, Cantor Fitzgerald, Cantor, Jefferies, Piper Sandler, TXRH, Wells, Wells Fargo, Emerson, Oppenheimer, Goldman Sachs, Bonnie Herzog's, MarketWise, Redburn, Johnson Organizations: Boeing, Delta, Air Lines, Citi, Spotify, RBC, Western Alliance, Novo Nordisk, Arcos, American, Crescent Energy, Fortrea Holdings, ISI, Aspen Technology, Emerson, JPMorgan, Constellation Brands, Constellation, UBS, Bank of America, Norfolk Southern, of America, Norfolk, CSG Systems, Communication Service, Financial Services, Technology, Healthcare, Westinghouse, Johnson, Innovative Medicine, Pharmaceutical Locations: Europe, China, Arcos, 4Q24, reaccelerate, Aspen, Norfolk, Israel

☆ Friday's analyst calls: Big drug stock upgrade, Alibaba downgrade, a new AI play
▼ + stars: | 2023-12-01 | by ( Sarah Min | ) www.cnbc.com time to read: +7 min

The analyst lowered her price target to $99 from $106 per share. The new price target implies just a 5% gain from Thursday's close. The analyst's $115 price target, hiked from $70 previously, implies 43% upside from where the stock closed Thursday, at $80.36. ET: Morgan Stanley downgrades Alibaba Morgan Stanley cut Alibaba to equal-weight from overweight and lowered the firm's price target to $90 from $110. The analyst's $190 price target implies shares can rise just 2.6% from where they closed Thursday.

Persons: JPMorgan downgrades, Jessica Fye, Fye, Sarah Min, Wells Fargo, Andrew Nowinski, GenAI, Nowinski, FactSet, — Sarah Min, Morgan Stanley downgrades Alibaba Morgan Stanley, Alibaba, Morgan Stanley, PDD, John Melloy, Jason Bazinet, Bazinet, Johnson, Danielle Antalffy, Antalffy, Robert Ohmes, — John Melloy Organizations: CNBC, Spotify, JPMorgan, Investors, U.S, PDD Holdings, Citi, UBS, Johnson, Pharma, Bank of America, of America, Costco Locations: BioNTech, Thursday's, Wells Fargo, China, Darzalex, DARZALEX

☆ Here are Tuesday's biggest analyst calls: Apple, Rivian, Nvidia, Boeing, Affirm, Datadog, Amazon & more
▼ + stars: | 2023-11-28 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Tuesday's biggest calls on Wall Street: UBS downgrades ChargePoint to neutral from buy UBS said it's cautious on the EV charging company's growth outlook. " Citi reiterates Nvidia as buy Citi said it's sticking with its buy rating on shares of Nvidia. " Wells Fargo downgrades Booz Allen Hamilton to equal weight from overweight Wells said investors should wait for a better entry point for the defense contractor. Raymond James upgrades Crocs to strong buy from outperform Raymond James said it sees an attractive entry point for the show company. Wells Fargo reiterates Amazon as overweight Wells said international trends for Amazon remain healthy.

Persons: UBS downgrades ChargePoint, it's, Wells, Booz Allen Hamilton, Bernstein, Raymond James, Crocs, CROX's, Estee Lauder, Jefferies, underperform Jefferies, Evercore, Rivian, Piper Sandler downgrades Shopify, Piper, Piper Sandler, Canaccord, TD Cowen, Datadog, TD, Truist, it's bullish, Ingersoll Rand Organizations: UBS downgrades, UBS, JPMorgan, Apple, Citi, Nvidia, HSBC, RBC, Boeing, Lexeo Therapeutics, Bank of America, Virtu, Logistics, Industry Locations: U.S, DDOG, India, Ingersoll

☆ Jim Cramer knocks down a new analyst sell rating on a medtech stock as shortsighted
▼ + stars: | 2023-11-27 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Wall Street was mixed Monday after the Dow , the S & P 500 and the Nasdaq finished higher for the fourth straight week. Jim Cramer took issue with the note, saying Monday that GEHC's body scan machines are key in the administration of a new class of Alzheimer's drugs. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Outperformance, Jim, Jim Cramer's Organizations: CNBC, Dow, Nasdaq, GE Healthcare, UBS

Analysts attended earnings calls in the third quarter armed with questions for healthcare and consumer companies about the potential effect on their sales from the growing popularity of these drugs, known as GLP-1 agonists. A Reuters analysis of earnings transcripts for the third quarter showed "GLP-1" or alternatives like "obesity" or "weight-loss medications" were mentioned 256 times across 29 U.S. and European healthcare and consumer companies. That's more than double the mentions for the second quarter, when those phrases came up 127 times. While some consumer companies have talked about factors such as fewer calories being consumed, "these kind of large extrapolations" seem to be a bit of a stretch, said BMO Capital analyst Evan Seigerman. For big pharma manufacturers like Pfizer (PFE.N) and Amgen (AMGN.O), analyst questions were aimed at their obesity drug candidates.

Persons: Lilly, George Frey, Jeff Jonas, it's, Eli Lilly's, John Furner, Mondelez, Eli Lilly, Evan Seigerman, LVMH, Rajesh Kumar, Jonas, Bhanvi Satija, Savyata Mishra, Arpan Varghese, David Gaffen, Shounak Organizations: Novo Nordisk, Pharmacy, REUTERS, Gabelli, Novo, Walmart, Walmart U.S, Hershey, Truist Securities, Krispy, BMO Capital, Danish, pharma, Pfizer, Devices, HSBC, Thomson Locations: Provo , Utah, U.S, United States, Novo, Bengaluru

Search resuls for: "medtech"

25 mentions found